MedTrace Logo

Genetic Predisposition to High Blood Pressure

NCT07181213 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-02-02

No results posted yet for this study

Summary

Primary aldosteronism (PA) is a known but underdiagnosed cause of high blood pressure. It is estimated that more than 10% of all people with high blood pressure (HT) suffer from PA, which is often caused by aldosterone-producing adrenal cortical tumors (APAs).

In a pilot study with 35 patients with APAs leading to hypertension, the investigators have identified a genetic variant in a presumed Calcium-channel gene. The variant was significantly overrepresented in patients with APAs compared to the normal population (12% compared to approximately 4%). Interestingly, all patients having APAs and the variant were men.

The SCAPIS study is a world-unique Swedish research study in the field of heart/lungs, in which 30,000 randomly selected people between the ages of 50-64 participated. The study is a collaboration between the universities of Gothenburg, Lund, Linköping, Uppsala and Umeå, as well as the Karolinska Institute in Stockholm. In Linköping, about 5,000 persons participated.

The investigators have now screened 4762 persons from the SCAPIS study for this variant and found it in little less than 6%. Overall, patients with the variant had more often been diagnosed with HT and were mote often treated for HT as well. Interestingly, this difference was only found in men.

The investigators now want to investigate the following:

1. identify those persons with the genetic variant and HT that have PA,
2. identify those persons with PA that have APAs/unilateral disease,
3. identify how many patients with APAs/unilateral disease can be cured by surgery.

Conditions

  • Hypertension
  • Primary Aldosteronism
  • Genetic Predisposition to Disease

Interventions

PROCEDURE

Adrenalectomy

Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension

Sponsors & Collaborators

  • Linkoeping University

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07181213 on ClinicalTrials.gov